The Effect of Vitamin D on Attention Deficit Hyperactivity Disorder

The effect of vitamin D supplementation on inflammatory cytokines (Interleukin 6, Tumor Necrosis Factor alpha), Brain-derived neurotrophic factor (BDNF), Dopamine, Serotonin, Paroxonase-1 enzyme (PON-1),Total Antioxidant Capacity (TAC), 8-Isoprostane, Soluble intercellular adhesion molecule-1(sICAM-1) and Soluble vascular cell adhesion molecule-1(sVCAM-1) in school- aged children with Attention Deficit Hyperactivity Disorder

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016102324081N2

Enrollment

Registered

2017-07-22

Start date

2016-10-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit Hyperactivity Disorder. Disturbance of activity and attention

Interventions

Intervention 1: Intervention group: vitamin D3, 25 mcg oral tablet manufactured by Jalinous, twice a day for 3 months. Intervention 2: Control group: placebo, 25 mcg oral tablet manufactured by Jalino

Treatment - Drugs

Intervention group: vitamin D3, 25 mcg oral tablet manufactured by Jalinous, twice a day for 3 months

Control group: placebo, 25 mcg oral tablet manufactured by Jalinous, twice a day for 3 months

Eligibility

Sex/Gender

All

Age

6 Years to 12 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: The age between 6-12 year old ; Children with ADHD according to DSM-V criteria ; Children taking Ritalin Exclusion criteria: Children use other supplements except vitamin D3 ; Discontinue taking Ritalin and vitamin D ; Medical conditions (e.g., infectious or cardiovascular diseases, diabetes ,hypertension, Hyperthyroidism, Digestive diseases, liver or kidney diseases, respiratory diseases and allergies) ; Neurological diseases such as seizures, epilepsy and ... except ADHD ; History of severe head trauma ; BMI above the 85th percentile ; Taking any medicine except Ritalin

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Interleukin 6 (IL-6). Timepoint: Pre-intervention/post intervention. Method of measurement: ELISA - pg/ml.;Tumor Necrosis Factor alpha (TNF-a). Timepoint: Pre-intervention/post intervention. Method of measurement: ELISA-pg/ml.;Brain-derived neurotrophic factor (BDNF). Timepoint: Pre-intervention/post intervention. Method of measurement: ELISA - pg/ml.;Dopamine. Timepoint: Pre-intervention/post intervention. Method of measurement: ELISA - pg/ml.;Serotonin. Timepoint: Pre-intervention/post intervention. Method of measurement: ELISA - ng/ml.;Total Antioxidant Capacity (TAC). Timepoint: Pre-intervention/post intervention. Method of measurement: ELISA-pg/ml.;8-Isoprostan. Timepoint: Pre-intervention/post intervention. Method of measurement: ELISA-pg/ml.;Paroxonase-1(PON-1). Timepoint: Pre-intervention/post intervention. Method of measurement: ELISA-pg/ml.;Soluble intercellular adhesion molecule-1 (sICAM-1). Timepoint: Pre-intervention/post intervention. Method of measurement: ELISA-ng/dl.;Soluble vascular cell adhesion molecule-1 (sVCAM-1). Timepoint: Pre-intervention/post intervention. Method of measurement: ELISA-ng/dl.	—

Measure

Time frame

Interleukin 6 (IL-6). Timepoint: Pre-intervention/post intervention. Method of measurement: ELISA - pg/ml.;Tumor Necrosis Factor alpha (TNF-a). Timepoint: Pre-intervention/post intervention. Method of measurement: ELISA-pg/ml.;Brain-derived neurotrophic factor (BDNF). Timepoint: Pre-intervention/post intervention. Method of measurement: ELISA - pg/ml.;Dopamine. Timepoint: Pre-intervention/post intervention. Method of measurement: ELISA - pg/ml.;Serotonin. Timepoint: Pre-intervention/post intervention. Method of measurement: ELISA - ng/ml.;Total Antioxidant Capacity (TAC). Timepoint: Pre-intervention/post intervention. Method of measurement: ELISA-pg/ml.;8-Isoprostan. Timepoint: Pre-intervention/post intervention. Method of measurement: ELISA-pg/ml.;Paroxonase-1(PON-1). Timepoint: Pre-intervention/post intervention. Method of measurement: ELISA-pg/ml.;Soluble intercellular adhesion molecule-1 (sICAM-1). Timepoint: Pre-intervention/post intervention. Method of measurement: ELISA-ng/dl.;Soluble vascular cell adhesion molecule-1 (sVCAM-1). Timepoint: Pre-intervention/post intervention. Method of measurement: ELISA-ng/dl.

—

Secondary

Measure	Time frame
Symptoms. Timepoint: Pre-intervention/post intervention. Method of measurement: Conner's Parent Rating Scale-Revised [S], ADHD Rating scale-IV, Parent Rating of Evening and Morning Behavior-Revised.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026